News

Latest news

Hide mandatory notifications of trade
  • Bionor announces option issue to key employees

    Financial .2015

    (Oslo, Norway, 12 August 2015) The Board of Directors of Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has approved an updated option program for the next four year period, pending the continuing support of the shareholders through yearly grants of authorizations for share issues under the company’s incentive program.

  • H1 2015 Interim Financial Report

    Financial .2015

    Bionor Pharma ASA
    Interim Financial Report
    1 January – 30 June 2015
    Unaudited

    Oslo, 12 August 2015

  • Bionor notice of results for the six months ended 30 June 2015

    Financial .2015

    (Oslo, Norway, 5 August 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, will report its half year financial results for the six months ended 30 June 2015 on 12 August 2015 at 07:30am CEST.

  • Bionor enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II

    Financial .2015

    (Oslo, Norway, 16 July 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, has signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax®) for use in a planned multicenter clinical Phase II study of Bionor’s most advanced and proprietary vaccine, Vacc-4x, with romidepsin.

  • Share capital increase registered

    Financial .2015

    (Oslo, Norway, 23 June 2015) With reference to the announcement made on 18 June 2015 regarding issuance of shares to former employee Birger Sørensen under a share option agreement, the share capital increase has now been registered in the Companies Register.

  • Bionor Pharma ASA issues shares to board members

    Financial .2015

    (Oslo, Norway, 23 June 2015) In accordance with the resolution by the Annual General Meeting of Bionor Pharma ASA (OSE: BIONOR) on 13 May 2015, all board members have been offered to subscribe shares in the Company valued at NOK 100,000 and the Chairman of the Board has been offered to subscribe shares valued at NOK 200,000.

  • Exercise of share options

    Financial .2015

    (Oslo, Norway, 18 June 2015) The Board of Directors of Bionor Pharma ASA (OSE:BIONOR) has resolved to issue 666,667 new shares in the Company based on options exercised by former employee Birger Sørensen.

  • Bionor appoints new Chairman and three Non-Executive Directors

    Financial .2015

    (Oslo, Norway, 13 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV announces, following today’s Annual General Meeting, the appointment of a new Chairman and three Non-Executive Directors.

  • Bionor Pharma: Annual General Meeting Approves All Items

    Financial .2015

    (Oslo, 13 May 2015) The Annual General Meeting of Bionor Pharma ASA today adopted all the items as proposed on the agenda.

  • Bionor Pharma - First Quarter 2015 results

    Financial .2015

    (Oslo, 13.05.2015) Bionor Pharma ASA (OSE: BIONOR) announced today its financial results for the first quarter 2015 and update on its clinical development program.